Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Cardiovascular Benefits of Semaglutide - Clinical Trial Interpretation

    2024-07-23

    A recent study published in the international journal Diabetes Care, titled "Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT," has revealed a new benefit of Semaglutide - the cardiovascular benefits. Read More
  • Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial

    2024-06-24

    A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV Read More
  • The Complement System: A Frontier in Drug Development

    2024-06-12

    The complement system has long been recognized as a crucial component of the innate immune system, acting as the first line of defense against invading pathogens. However, recent advancements in understanding this intricate network have unveiled its multifaceted roles in various physiological proces Read More
  • Tirzepatide Approved by NMPA for Type II Diabetes

    2024-05-21

    On May 21st, the Chinese National Medical Products Administration (NMPA) approved Tirzepatide (brand name Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Lilly, for the improvement of glycemic control in adults wi Read More
  • Case Study of Flow Chemistry in the Synthesis of Pharmaceutical Ingredient Belzutifan

    2024-04-23

    IntroductionIn a previous article, we discussed when to consider using flow chemistry over conventional batch processes for chemical synthesis. One compelling example highlighting the advantages of flow chemistry comes from the manufacturing route development for belzutifan, a recently approved drug Read More
  • Scaling the Everest of Pharma Synthesis: A Deep Dive into Eribulin's Journey

    2024-04-19

    As one steps into the realm of pharmaceutical discovery, the name Eribulin, also known as Halaven, rings a powerful note. First approved in 2010 by Eisai, this non-peptide drug, intricate in its synthesis and impressive in the magnitude of its medical impact, has been nothing short of groundbreaking Read More
  • The Melt-In-Your-Mouth Medicine

    2024-03-01

    Why Choose Orally Dissolving Tablets (ODTs)?Orally dissolving tablets (ODTs) have revolutionized the pharmaceutical industry and patient care by enhancing drug life-cycle management and offering convenient dosing for patients who have difficulty swallowing, such as children, the elderly, and psychia Read More
  • Cancer, radiopharma & RDCs

    2024-02-27

    Market potential of radiopharma & RDCsRDCs are currently being developed for cancer. According to the WHO IARC, in 2022, the five most common cancers resulted in 19,956,054 new cases and 9,736,520 deaths. It is estimated that by 2050, the incidence of all cancers will reach 35.3 million. Consequentl Read More
  • Stability of Pharmaceutical Industry Supply Chains Against the Backdrop of Deglobalization

    2024-02-23

    In the tide of globalization, supply chains, as the important link connecting the economies of various countries, play an extremely important role. However, in recent years, the trend of deglobalization has gradually emerged, bringing unprecedented challenges to global supply chains. Especially in t Read More
  • Total 3 pages  Go to Page
  • Go